

---

## Cellavision Q1 2025 - EMEA Drove Sales Growth

Redeye comments on Cellavision's first quarter 2025, which saw organic sales growth of 14%, an outstanding figure. Growth was mainly driven by instrument sales in EMEA. The outlook for the rest of the year is positive, with the caveat that an appreciating SEK will have a negative effect on the final growth rate.

**Read more and download the Research Update.**

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

**Cellavision Q1 2025 - EMEA Drove Sales Growth**